Brystkræft I kombination med docetaxel er den anbefalede initialdosis af Xeloda til behandling af metastatisk brystkræft 1250 mg/ m2 to gange dagligt i 14 dage efterfulgt af 7 dages pause, kombineret med docetaxel 75 mg/ m2 givet som 1 times intravenøs infusion hver 3. uge.
Breast cancer In combination with docetaxel, the recommended starting dose of Xeloda in the treatment of metastatic breast cancer is 1250 mg/ m2 twice daily for 14 days followed by a 7-day rest period, combined with docetaxel at 75 mg/ m2 as a 1 hour intravenous infusion every 3 weeks.